Atria Investments Inc raised its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 6.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,365 shares of the biopharmaceutical company’s stock after purchasing an additional 737 shares during the quarter. Atria Investments Inc’s holdings in Agios Pharmaceuticals were worth $373,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of the business. Quest Partners LLC lifted its holdings in Agios Pharmaceuticals by 139.6% during the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,283 shares during the last quarter. Intech Investment Management LLC bought a new position in Agios Pharmaceuticals during the 3rd quarter worth approximately $892,000. Charles Schwab Investment Management Inc. lifted its holdings in Agios Pharmaceuticals by 1.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 465,620 shares of the biopharmaceutical company’s stock worth $20,687,000 after buying an additional 8,093 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in Agios Pharmaceuticals by 20.5% during the 3rd quarter. Fisher Asset Management LLC now owns 855,328 shares of the biopharmaceutical company’s stock worth $38,002,000 after buying an additional 145,416 shares during the last quarter. Finally, Loomis Sayles & Co. L P lifted its holdings in Agios Pharmaceuticals by 36.4% during the 3rd quarter. Loomis Sayles & Co. L P now owns 612,366 shares of the biopharmaceutical company’s stock worth $27,208,000 after buying an additional 163,503 shares during the last quarter.
Insider Activity
In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is owned by insiders.
Analyst Ratings Changes
Read Our Latest Analysis on Agios Pharmaceuticals
Agios Pharmaceuticals Price Performance
AGIO opened at $30.93 on Monday. Agios Pharmaceuticals, Inc. has a 12 month low of $27.14 and a 12 month high of $62.58. The stock has a market cap of $1.77 billion, a P/E ratio of 2.73 and a beta of 0.90. The stock’s 50 day moving average price is $33.70 and its 200 day moving average price is $41.76.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
See Also
- Five stocks we like better than Agios Pharmaceuticals
- P/E Ratio Calculation: How to Assess Stocks
- How to Build the Ultimate Everything ETF Portfolio
- 3 Small Caps With Big Return Potential
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Golden Cross Stocks: Pattern, Examples and Charts
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report).
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.